INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Centene Corporation (CNC) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
If you suffered substantial losses and wish to serve as lead plaintiff of the Centene class action lawsuit, please provide your information here:
You can also contact attorneys J.C. Sanchez or of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Centene class action lawsuit must be filed with the court no later than September 8, 2025.
CASE ALLEGATIONS: Centene is a healthcare enterprise that provides fully integrated services to government-sponsored and commercial healthcare programs, focusing on underinsured and uninsured individuals.
The Centene class action lawsuit alleges that defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to Centene's projected revenue outlook and anticipated growth while also touting enrollment rates and low morbidity. In truth, Centene's optimistic reports and promises regarding Centene's inflated guidance fell short of reality when a preliminary analysis of over two-thirds of Centene's marketplace share showed lower-than-anticipated enrollment and increased aggregate market morbidity, according to the complaint.
The Centene class action lawsuit further alleges that, on July 1, 2025, Centene withdrew its 2025 guidance. Particularly, following an analysis of the 2025 Health Insurance Marketplace, Centene's overall market growth across 22 states, or 72% of Centene's marketplace membership, was lower than expected, according to the complaint. Centene also stated that this preliminary analysis resulted in a reduction of its previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75, the Centene class action lawsuit alleges. On this news, the price of Centene stock fell by more than 40%.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Centene securities during the class period to seek appointment as lead plaintiff in the Centene class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Centene class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Centene class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Centene class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
12 minutes ago
- Associated Press
PCI Pal Launches Fraud Management Suite to Strengthen Contact Center Security
CHARLOTTE, N.C.--(BUSINESS WIRE)--Jul 29, 2025-- PCI Pal ® (LON: PCIP) today announced the launch of its new Fraud Management Suite, beginning with AI-powered risk scoring for customer engagements. Designed to protect against rising card-not-present (CNP) fraud, the new capability delivers real-time risk insights to agents and AI bots before a payment is collected — reducing chargebacks and revenue loss without adding friction to the customer experience. CNP fraud remains one of the most costly threats for global businesses. While e-commerce channels benefit from tools like 3D Secure and biometric authentication, the voice channel — still central to many contact centers — has lacked equivalent protection. PCI Pal is closing that gap with a platform-led approach that combines security, compliance, and usability. 'This is the first step in a multi-product journey to deliver continuous value to our customers and partners,' said Alessandro Dalla Volta, VP of Product at PCI Pal. 'By embedding risk scoring into our Secure Payments Suite via an intuitive agent interface and a single API, we're giving contact centers powerful tools to detect fraud early and authenticate their customers seamlessly — across agents and bots using digital channels as needed.' A Smarter Way to Fight Fraud The new Fraud Management Suite helps organizations respond to evolving threats with: Built for the Modern Contact Center 'AI is transforming how we approach security — not just in detecting fraud, but in anticipating it,' said Mufti Monim, CTO of PCI Pal. 'This launch lays the groundwork for a more intelligent and adaptive platform, that secures payments across all channels while enhancing both customer and agent experiences. It's the first step in a broader roadmap to unify fraud prevention, compliance, and customer experience into one seamless, scalable platform.' Availability AI-powered risk scoring is now available as part of the PCI Pal platform. Learn more at About PCI Pal PCI Pal ® (LON: PCIP) is a leading provider of secure payment solutions for business communications. PCI Pal's mission is to safeguard reputations and trust by securing payments wherever customer engagement occurs. With its patented, cloud-based platform, PCI Pal enables organizations to take secure payments via voice, chat, email, and social, while ensuring compliance with industry standards such as PCI DSS. For more information, visit View source version on CONTACT: Media Contact Nicole Von Seggern [email protected] KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA INDUSTRY KEYWORD: BANKING SOFTWARE OTHER RETAIL PROFESSIONAL SERVICES FINTECH DATA MANAGEMENT SPECIALTY PAYMENTS TECHNOLOGY ARTIFICIAL INTELLIGENCE RETAIL FINANCE OTHER TECHNOLOGY SOURCE: PCI Pal Copyright Business Wire 2025. PUB: 07/29/2025 03:00 AM/DISC: 07/29/2025 03:00 AM
Associated Press
12 minutes ago
- Associated Press
Tide Now Supports Over 1.5 Million Small Businesses Globally
LONDON--(BUSINESS WIRE)--Jul 29, 2025-- Tide, the UK's leading business management platform, today announces it has surpassed 1.5 million members globally. Tide has added over 500,000 members since September 2024, with the UK now at 750,000 and India at more than 750,000. Tide's share of the UK market has grown to 13%. Tide continues to expand its presence in Germany. Oliver Prill, CEO of Tide, commented: 'Reaching 1.5 million members globally and lending more than £1 billion to UK SMEs are major milestones for Tide. These achievements reflect our commitment to helping small businesses save time and money by giving them business critical tools across finance, admin and related commercial services that they need, to grow. We are enriching and expanding our range of highly connected products at pace. We will continue to explore markets to boost the geographic footprint of our business management platform.' Highlights: View source version on CONTACT: Lloyd Purnell PR and Communications Lead, UK, Tide. Email:[email protected] KEYWORD: EUROPE IRELAND UNITED KINGDOM INDUSTRY KEYWORD: DATA MANAGEMENT SUSTAINABILITY TECHNOLOGY FINANCE SMALL BUSINESS FINTECH BANKING APPS/APPLICATIONS PROFESSIONAL SERVICES ENVIRONMENTAL POLICY ENVIRONMENT ARTIFICIAL INTELLIGENCE PAYMENTS SOFTWARE DATA ANALYTICS SOURCE: Tide Copyright Business Wire 2025. PUB: 07/29/2025 03:00 AM/DISC: 07/29/2025 03:01 AM
Business Wire
29 minutes ago
- Business Wire
Exonate plans ‘CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease
CAMBRIDGE, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical trial for its lead candidate EXN407. The CLEAR-DE (Clinical Evaluation of a New Eye Drop for Alleviating Retinopathy in Diabetic Eye Disease) trial will further evaluate the clinical efficacy, optimal dosing and safety profile of EXN407 in patients with non-proliferative diabetic retinopathy (NPDR). The progression to a Phase IIb clinical study follows encouraging results from Exonate's Phase Ib/IIa study in March 2024. In the study, lead candidate EXN407 met its primary safety and tolerability endpoints, with no drug-related serious adverse events, and high patient compliance. Importantly, exploratory efficacy signals showed a reduction in vascular leakage, a key pathological driver in diabetic retinopathy. The Phase IIb trial to investigate the efficacy of EXN407 in NPDR patients is planned to begin in early 2026, with 140 patients currently enrolled across multiple sites in Australia, the Middle East and China. Diabetic retinopathy (DR) is a leading cause of vision loss globally. An estimated one-third of the nearly 500 million people living with diabetes are affected by NPDR, the early stage of diabetic eye disease, which can lead to more severe, vision-threatening complications. Current therapeutic approaches involve monthly intraocular injections, initiated only after symptoms appear. This limits opportunities for early therapeutic benefit, and due to the invasive nature and frequency, is often deferred until irreversible damage has occurred. EXN407 is a first-in-class, twice-daily topical formulation of a selective SRPK1 inhibitor – a minimally-invasive approach with potential to become the first effective eye-drop therapy for NPDR and diabetic macular oedema (DME). Designed to modulate expression of vascular endothelial growth factor (VEGF) via alternative mRNA splicing, EXN407 selectively inhibits the pro-angiogenic isoforms that drive disease progression, causing abnormal and leaky blood vessel formation in the retina. ' The Phase Ib/IIa data demonstrated the clear potential of EXN407 as a non-invasive treatment for diabetic eye disease, ' said Dr. Catherine Beech, Chief Executive Officer of Exonate. ' This therapy could transform the treatment landscape for early-stage disease by providing clinical benefit while avoiding the burden of injections, representing a significant advancement for patients and physicians alike. We're excited to progress to the CLEAR-DE Phase IIb trial and are actively seeking strategic partners to support its execution.' For more information about Exonate's pipeline and clinical development plans, please visit:
